(Q36341541)

13 August 2017

title

A copayment increase for prescription drugs: the long-term and short-term effects on use and expenditures (English)

1 reference

13 August 2017

Teresa B Gibson

1

1 reference

13 August 2017

Catherine G McLaughlin

series ordinal

2

1 reference

13 August 2017

Dean G Smith

series ordinal

3

1 reference

13 August 2017

language of work or name

1 reference

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

42

1 reference

13 August 2017

issue

3

1 reference

13 August 2017

page(s)

293-310

1 reference

Interaction terms in logit and probit models

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.5034%2FINQUIRYJRNL_42.3.293

The U.S. pharmaceutical industry: why major growth in times of cost containment?

21 January 2018

1 reference

https://api.crossref.org/works/10.5034%2FINQUIRYJRNL_42.3.293

Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.5034%2FINQUIRYJRNL_42.3.293

Methods for analyzing health care utilization and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.5034%2FINQUIRYJRNL_42.3.293

Explaining drug spending trends: does perception match reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.5034%2FINQUIRYJRNL_42.3.293

Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.5034%2FINQUIRYJRNL_42.3.293

Pharmacy benefits and the use of drugs by the chronically ill.

21 January 2018

1 reference

https://api.crossref.org/works/10.5034%2FINQUIRYJRNL_42.3.293

Matching As An Econometric Evaluation Estimator: Evidence from Evaluating a Job Training Programme

21 January 2018

1 reference

https://api.crossref.org/works/10.5034%2FINQUIRYJRNL_42.3.293

Financial incentives and drug spending in managed care

21 January 2018

1 reference

https://api.crossref.org/works/10.5034%2FINQUIRYJRNL_42.3.293

The effect of incentive-based formularies on prescription-drug utilization and spending

21 January 2018

1 reference

https://api.crossref.org/works/10.5034%2FINQUIRYJRNL_42.3.293

Employer drug benefit plans and spending on prescription drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.5034%2FINQUIRYJRNL_42.3.293

How do incentive-based formularies influence drug selection and spending for hypertension?

21 January 2018

1 reference

https://api.crossref.org/works/10.5034%2FINQUIRYJRNL_42.3.293

Effects of Medicare payment changes on nursing home staffing and deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.5034%2FINQUIRYJRNL_42.3.293

Performance of generalized estimating equations in practical situations.

21 January 2018

1 reference

https://api.crossref.org/works/10.5034%2FINQUIRYJRNL_42.3.293

Effect of a three-tier prescription copay on pharmaceutical and other medical utilization

21 January 2018

1 reference

https://api.crossref.org/works/10.5034%2FINQUIRYJRNL_42.3.293

Health status and heterogeneity of cost-sharing responsiveness: how do sick people respond to cost-sharing?

21 January 2018

1 reference

https://api.crossref.org/works/10.5034%2FINQUIRYJRNL_42.3.293

The central role of the propensity score in observational studies for causal effects

21 January 2018

1 reference

https://api.crossref.org/works/10.5034%2FINQUIRYJRNL_42.3.293

Adverse events associated with prescription drug cost-sharing among poor and elderly persons

21 January 2018

1 reference

https://api.crossref.org/works/10.5034%2FINQUIRYJRNL_42.3.293

A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for Heteroskedasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.5034%2FINQUIRYJRNL_42.3.293

10.5034/INQUIRYJRNL_42.3.293

21 January 2018

Identifiers

DOI

0 references

1 reference